Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 294 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Extensive-stage Small Cell Lung Carcinoma Clear all
Completed Phase 2 Interventional Results available

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage

NCT00887159
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
Interventions
Cisplatin, Cixutumumab, Etoposide, Laboratory Biomarker Analysis, Vismodegib
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
301
States / cities
Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 205 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 10, 2026, 6:10 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 10, 2026, 6:10 AM EDT
Active, not recruiting Phase 1 Interventional

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
Tarlatamab, Carboplatin, Etoposide, Atezolizumab, Durvalumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
9
States / cities
Los Angeles, California • Newark, Delaware • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 10, 2026, 6:10 AM EDT
Recruiting Phase 2 Interventional

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

NCT07339059
View directory record Official record
Conditions
Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
Sacituzumab govitecan, Atezolizumab, Durvalumab
Drug
Lead sponsor
Bindu R Potugari
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 10, 2026, 6:10 AM EDT
Completed Phase 3 Interventional

Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00003299
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
19
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 10, 2026, 6:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

NCT01217411
View directory record Official record
Conditions
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 10, 2026, 6:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

NCT04670445
View directory record Official record
Conditions
Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma, Unresectable Stage III Non-Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Stage IV Merkel Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma, Stage IV Basal Cell Carcinoma, Stage IV Breast Cancer, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Hepatocellular Cancer, Stage IV Renal Cell Carcinoma, Stage IV Bladder Cancer, Stage IV Head and Neck Squamous Cell Carcinoma, Stage IV Cervical Cancer, Stage IV Endometrial Cancer, Stage IV Mesothelioma, Immunotherapy, Immune Checkpoint Inhibitors
Interventions
Educational Video and QPL List, Usual Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 10, 2026, 6:10 AM EDT
Recruiting Phase 2 Interventional

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

NCT04696575
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Carboplatin, Etoposide, Lamivudine
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 10, 2026, 6:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

NCT05703971
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
quaratusugene ozeplasmid, atezolizumab
Biological
Lead sponsor
Genprex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Lone Tree, Colorado • St Louis, Missouri • Canton, Ohio + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 10, 2026, 6:10 AM EDT
Terminated Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer

NCT00003496
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 10, 2026, 6:10 AM EDT
Active, not recruiting Phase 2 Interventional

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

NCT06449209
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Interventions
BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 10, 2026, 6:10 AM EDT
Completed Phase 1 Interventional

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

NCT03898791
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
LY3295668 Erbumine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Fayetteville, Arkansas • Denver, Colorado • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 10, 2026, 6:10 AM EDT
Recruiting Phase 1 Interventional

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

NCT07139990
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer, Sarcoma,Soft Tissue, HNPCC
Interventions
Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR, Cohort D: Resectable Head & Neck Squamous Cell Carcinoma (HNSCC) PULSAR/SAbR
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 10, 2026, 6:10 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

NCT00028925
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, topotecan hydrochloride, WBRT
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
23
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 10, 2026, 6:10 AM EDT
Completed Phase 1 Interventional

Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors

NCT00388089
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, topotecan hydrochloride, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Oct 10, 2026, 6:10 AM EDT
Terminated Phase 1 Interventional

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

NCT00088933
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Recurrent Colon Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Rectal Cancer, Recurrent Small Cell Lung Cancer, Stage IV Colon Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Rectal Cancer
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, docetaxel, sargramostim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 10, 2026, 6:10 AM EDT
Terminated Phase 2 Interventional Results available

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

NCT04923776
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Carboplatin, Etoposide, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 10, 2026, 6:10 AM EDT
Terminated Phase 3 Interventional

Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

NCT01555710
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
Carboplatin, Palifosfamide-tris, Etoposide
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
40
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Rosa, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 10, 2026, 6:10 AM EDT
Completed Phase 2 Interventional

Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00005646
View directory record Official record
Conditions
Lung Cancer
Interventions
paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
5
States / cities
Columbia, Missouri • Syracuse, New York • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 10, 2026, 6:10 AM EDT
Withdrawn Phase 2 Interventional

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT03402880
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma
Interventions
Pembrolizumab, Epacadostat, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Duarte, California • South Pasadena, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 10, 2026, 6:10 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00041054
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, etoposide, exisulind
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
81
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 10, 2026, 6:10 AM EDT
Completed Phase 1 Interventional

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

NCT00016237
View directory record Official record
Conditions
Bladder Cancer, Kidney Cancer, Lung Cancer
Interventions
tucotuzumab celmoleukin
Biological
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 10, 2026, 6:10 AM EDT
Terminated Phase 2 Interventional Results available

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

NCT04373369
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Vorolanib, Atezolizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 10, 2026, 6:10 AM EDT
Terminated Phase 2 Interventional

KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT05027867
View directory record Official record
Conditions
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
Interventions
KRT-232
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 10, 2026, 6:10 AM EDT